Category Archives: News

$3 million investment to perfect Alzheimer’s drug.

$3m Raised for Alzheimer’s Drug


NEW YORK – A consortium of four investors, including the Technion Research and Development Foundation Ltd. (TRDF), has completed a $3 million financing round for Israel-based Avraham Pharmaceuticals to further the development of a novel drug for Alzheimer’s disease.

The drug, ladostigil, is a molecule that combines components from the existing drugs Azilect and Exelon. Teva’s Azilect, for the treatment of Parkinson’s disease, was developed by Prof. Emeritus Moussa Youdim of the Technion-Israel Institute of Technology. Azilect is the only anti-Parkinson’s drug that has proven to have a disease-modifying effect. Novartis’s Exelon was developed by Prof. Marta Weinstock-Rosin of Hebrew University to treat Alzheimer’s disease.  
Ladostigil is the first Alzheimer’s drug with the potential to slow the progression of clinical symptoms for sustained periods of time, and to modify the pathology associated with the disease. In addition, studies of ageing rats have shown that the drug may be able to slow the progression to Alzheimers’s disease in patients diagnosed with MCI. It may also help treat mild cognitive impairment (MCI) and other neurodegenerative diseases.  
TRDF was joined in this latest round of fund-raising by Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University; Pontifax, a venture capital investor focusing on Israeli life sciences; and Clal Biotechnology Industries (CBI). Avraham Pharmaceuticals intends to use the $3 million to continue to advance its on-going Phase II proof-of-concept trial of ladostigil in patients with Alzheimer’s disease, and to begin a 36-month study to evaluate the safety and efficacy of ladostigil in patients diagnosed with MCI. This second study is expected to begin in the first quarter of 2012.  
“Avraham greatly appreciates the continued support of all its investors, which has enabled the company to advance development of both its Alzheimer’s disease-and MCI-directed drug products,” said Dr. Vincent R. Zurawski, CEO of Avraham Pharmaceuticals. 
Alzheimer’s disease is the most common cause of dementia worldwide, affecting about one in 20 people 65 years of age or older. MCI, defined as an intermediate stage between the expected cognitive decline of normal aging and the more pronounced decline of dementia, affects between 3% and 19% of people in the same age bracket. There is no proven treatment for MCI.

Prof. Moussa Youdim, Technion.


The Technion-Israel Institute of Technology is consistently ranked among the world’s leading science and technology universities.  Home to three of Israel’s five winners of the Nobel Prize in science, the Technion commands a worldwide reputation for its pioneering work in computer science, nanotechnology, biotechnology, energy, water-resource management, medicine, drug development, and aerospace.  Headquartered in New York City, the American Technion Society (ATS) promotes scientific and technological research and education at the Technion.


CONTACT: Jennifer Frey (Jennifer.frey@ats.org /212.407.6363)

$3 million investment to perfect Alzheimer’s drug.

$3m Raised for Alzheimer’s Drug


NEW YORK – A consortium of four investors, including the Technion Research and Development Foundation Ltd. (TRDF), has completed a $3 million financing round for Israel-based Avraham Pharmaceuticals to further the development of a novel drug for Alzheimer’s disease.

The drug, ladostigil, is a molecule that combines components from the existing drugs Azilect and Exelon. Teva’s Azilect, for the treatment of Parkinson’s disease, was developed by Prof. Emeritus Moussa Youdim of the Technion-Israel Institute of Technology. Azilect is the only anti-Parkinson’s drug that has proven to have a disease-modifying effect. Novartis’s Exelon was developed by Prof. Marta Weinstock-Rosin of Hebrew University to treat Alzheimer’s disease.  
Ladostigil is the first Alzheimer’s drug with the potential to slow the progression of clinical symptoms for sustained periods of time, and to modify the pathology associated with the disease. In addition, studies of ageing rats have shown that the drug may be able to slow the progression to Alzheimers’s disease in patients diagnosed with MCI. It may also help treat mild cognitive impairment (MCI) and other neurodegenerative diseases.  
TRDF was joined in this latest round of fund-raising by Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University; Pontifax, a venture capital investor focusing on Israeli life sciences; and Clal Biotechnology Industries (CBI). Avraham Pharmaceuticals intends to use the $3 million to continue to advance its on-going Phase II proof-of-concept trial of ladostigil in patients with Alzheimer’s disease, and to begin a 36-month study to evaluate the safety and efficacy of ladostigil in patients diagnosed with MCI. This second study is expected to begin in the first quarter of 2012.  
“Avraham greatly appreciates the continued support of all its investors, which has enabled the company to advance development of both its Alzheimer’s disease-and MCI-directed drug products,” said Dr. Vincent R. Zurawski, CEO of Avraham Pharmaceuticals. 
Alzheimer’s disease is the most common cause of dementia worldwide, affecting about one in 20 people 65 years of age or older. MCI, defined as an intermediate stage between the expected cognitive decline of normal aging and the more pronounced decline of dementia, affects between 3% and 19% of people in the same age bracket. There is no proven treatment for MCI.

Prof. Moussa Youdim, Technion.


The Technion-Israel Institute of Technology is consistently ranked among the world’s leading science and technology universities.  Home to three of Israel’s five winners of the Nobel Prize in science, the Technion commands a worldwide reputation for its pioneering work in computer science, nanotechnology, biotechnology, energy, water-resource management, medicine, drug development, and aerospace.  Headquartered in New York City, the American Technion Society (ATS) promotes scientific and technological research and education at the Technion.


CONTACT: Jennifer Frey (Jennifer.frey@ats.org /212.407.6363)

New Treatment for Alzheimers Disease

$3m Raised for Alzheimer’s Drug

NEW YORK – A consortium of four investors, including the Technion Research and Development Foundation Ltd. (TRDF), has completed a $3 million financing round for Israel-based Avraham Pharmaceuticals to further the development of a novel drug for Alzheimer’s disease.

The drug, ladostigil, is a molecule that combines components from the existing drugs Azilect and Exelon. Teva’s Azilect, for the treatment of Parkinson’s disease, was developed by Prof. Emeritus Moussa Youdim of the Technion-Israel Institute of Technology. Azilect is the only anti-Parkinson’s drug that has proven to have a disease-modifying effect. Novartis’s Exelon was developed by Prof. Marta Weinstock-Rosin of Hebrew University to treat Alzheimer’s disease.  
Ladostigil is the first Alzheimer’s drug with the potential to slow the progression of clinical symptoms for sustained periods of time, and to modify the pathology associated with the disease. In addition, studies of ageing rats have shown that the drug may be able to slow the progression to Alzheimers’s disease in patients diagnosed with MCI. It may also help treat mild cognitive impairment (MCI) and other neurodegenerative diseases.  


TRDF was joined in this latest round of fund-raising by Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University; Pontifax, a venture capital investor focusing on Israeli life sciences; and Clal Biotechnology Industries (CBI). Avraham Pharmaceuticals intends to use the $3 million to continue to advance its on-going Phase II proof-of-concept trial of ladostigil in patients with Alzheimer’s disease, and to begin a 36-month study to evaluate the safety and efficacy of ladostigil in patients diagnosed with MCI. This second study is expected to begin in the first quarter of 2012.  
“Avraham greatly appreciates the continued support of all its investors, which has enabled the company to advance development of both its Alzheimer’s disease-and MCI-directed drug products,” said Dr. Vincent R. Zurawski, CEO of Avraham Pharmaceuticals. 
Alzheimer’s disease is the most common cause of dementia worldwide, affecting about one in 20 people 65 years of age or older. MCI, defined as an intermediate stage between the expected cognitive decline of normal aging and the more pronounced decline of dementia, affects between 3% and 19% of people in the same age bracket. There is no proven treatment for MCI.

The Technion-Israel Institute of Technology is consistently ranked among the world’s leading science and technology universities.  Home to three of Israel’s five winners of the Nobel Prize in science, the Technion commands a worldwide reputation for its pioneering work in computer science, nanotechnology, biotechnology, energy, water-resource management, medicine, drug development, and aerospace.  Headquartered in New York City, the American Technion Society (ATS) promotes scientific and technological research and education at the Technion.


CONTACT: Jennifer Frey (Jennifer.frey@ats.org /212.407.6363)

New Treatment for Alzheimers Disease

$3m Raised for Alzheimer’s Drug

NEW YORK – A consortium of four investors, including the Technion Research and Development Foundation Ltd. (TRDF), has completed a $3 million financing round for Israel-based Avraham Pharmaceuticals to further the development of a novel drug for Alzheimer’s disease.

The drug, ladostigil, is a molecule that combines components from the existing drugs Azilect and Exelon. Teva’s Azilect, for the treatment of Parkinson’s disease, was developed by Prof. Emeritus Moussa Youdim of the Technion-Israel Institute of Technology. Azilect is the only anti-Parkinson’s drug that has proven to have a disease-modifying effect. Novartis’s Exelon was developed by Prof. Marta Weinstock-Rosin of Hebrew University to treat Alzheimer’s disease.  
Ladostigil is the first Alzheimer’s drug with the potential to slow the progression of clinical symptoms for sustained periods of time, and to modify the pathology associated with the disease. In addition, studies of ageing rats have shown that the drug may be able to slow the progression to Alzheimers’s disease in patients diagnosed with MCI. It may also help treat mild cognitive impairment (MCI) and other neurodegenerative diseases.  


TRDF was joined in this latest round of fund-raising by Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University; Pontifax, a venture capital investor focusing on Israeli life sciences; and Clal Biotechnology Industries (CBI). Avraham Pharmaceuticals intends to use the $3 million to continue to advance its on-going Phase II proof-of-concept trial of ladostigil in patients with Alzheimer’s disease, and to begin a 36-month study to evaluate the safety and efficacy of ladostigil in patients diagnosed with MCI. This second study is expected to begin in the first quarter of 2012.  
“Avraham greatly appreciates the continued support of all its investors, which has enabled the company to advance development of both its Alzheimer’s disease-and MCI-directed drug products,” said Dr. Vincent R. Zurawski, CEO of Avraham Pharmaceuticals. 
Alzheimer’s disease is the most common cause of dementia worldwide, affecting about one in 20 people 65 years of age or older. MCI, defined as an intermediate stage between the expected cognitive decline of normal aging and the more pronounced decline of dementia, affects between 3% and 19% of people in the same age bracket. There is no proven treatment for MCI.

The Technion-Israel Institute of Technology is consistently ranked among the world’s leading science and technology universities.  Home to three of Israel’s five winners of the Nobel Prize in science, the Technion commands a worldwide reputation for its pioneering work in computer science, nanotechnology, biotechnology, energy, water-resource management, medicine, drug development, and aerospace.  Headquartered in New York City, the American Technion Society (ATS) promotes scientific and technological research and education at the Technion.


CONTACT: Jennifer Frey (Jennifer.frey@ats.org /212.407.6363)

Bridge to Somewhere ~ Stanley Shalom Zielony Graduate Student Village, Technion City.

Blogged from Ha’aretz
Published 02:56 17.11.11
Latest update 02:56 17.11.11

The real innovation in the Technion’s new graduate housing lies in the bridges connecting the dorms, helping create communities of thinkers.

By Noam Dvir

The bridges of the new Graduate Students Village on the Technion campus in Haifa are bringing together a community of young researchers and scientists.

The village’s seven residential buildings are connected to each other by a system of wood and steel bridges that stand about eight meters above ground. Every afternoon these fill up with hundreds of parents and children who come down from their apartments to meet, talk and play. At the connecting points between the bridges and the buildings there are generous public spaces, equipped with wooden benches and wireless Internet. Parents can easily keep an eye on their children as they play in one of the playgrounds nearby.

The graduate student apartments with the bridge, which acts as a meeting place, a walkway and a place for leisure.

The Graduate Students Village is part of the Technion’s broad plan for attracting young minds, master’s and doctoral students who may become the next Nobel Prize winners. The model is simple: affordable housing, around NIS 1,700 per apartment including utilities, which enables students to concentrate on their research while assimilating into a cohesive community, and encourages them to settle down in the future at the Technion and in Haifa.

About eight years ago the Technion announced an architecture competition for a contemporary and appealing student village. Out of some 70 submissions to the competition, five architects made it to the final round, and the panel of judges ultimately chose the design submitted jointly by the architects Gaby Schwartz and Gidi Bar Orian.

The pair had studied architecture together at the Technion in the 1980s, so the project was a sort of homecoming. Bar Orian is known for his involvement in the design and preservation of residential buildings in Tel Aviv. Schwartz (of Schwartz Besnosoff Architects ) made his name with outstanding public buildings such as the new library at Kinneret College on the Sea of Galilee.

The village is located on the southwestern side of the campus, far away from the academic department buildings, and overlooks a natural and built landscape. The first decision that the architects made was to keep the natural forest in place far as was possible.

“Initially we thought of building low attached units, what is called a carpet, but the neighbors on the hill opposite always had a green landscape here and we didn’t want to spoil it for them,” Schwartz says. “Another decision was to avoid building huge support walls of the kind familiar in Haifa and to let the buildings become absorbed inward into the landscape.”

The chosen solution was a group of seven buildings, each five-stories high, that stand perpendicular to the mountain, with playgrounds and lawns between them. In the future, a community center will go up south of the residential buildings, and is set to include a kindergarten, clubhouse, and lecture hall.

Each building has some 30 apartments (218 in the housing complex overall ), which are arranged around three stairwells. Apartment sizes range from 60 to 100 square meters, with some having the option of “shifting” a room from one apartment to another to make it bigger or smaller.

The most important and innovative design component is a system of bridges that link up the interim levels of all the buildings and allow tenants to move around freely without needing to cross roads.

The experience of walking among the treetops is thrilling, and is reminiscent of works by the Japanese artist Tetsu Kondu, who deals with examining the relationship between man and heaven and earth. The buildings themselves look like giant masses that have had chunks “bitten” off.

“It’s meant to bring the landscape into the apartments,” Schwartz explains.

The seven buildings were intended for intensive use and wear and tear, so durable materials were selected – plaster for the facades, exposed concrete, suspended metal blinds, brick wall cover in the stairwells, and wooden lattices that create a separation between public- and semi-public spaces.

The entire village echoes the architecture of public housing complexes from the 1950s and 60s, particularly the bridge buildings designed by the architects Munio Gitai-Weinraub and Al Mansfeld in the Ramat Hadar neighborhood of Haifa. There too, the buildings are divided at mid-point by a public level that contains various usages for the benefit of the tenants, such as storage rooms and even a grocery store.

Forest living

Schwartz and Bar Orian agree with the comparison, but say their version takes the idea a step forward. “The public housing complexes in Israel were designed without any connection to the site. They were positioned at random without any link to the ground conditions. We tried to converse with the environment and with nature. The buildings in the village are ‘deformed’ in order to adjust to the landscape.”

The architects Liran Chechik and Nitzan Kalush have been living in the village for the past nine months. They moved there from junior faculty housing after their family grew. They deem the village a successful project, with “a whiff of colleges in Europe,” that enables community life and cooperation and makes you feel like sticking around for a long time.

“The public spaces have had a lot put into them, and generate a pretty lively community life – all relative to the Technion of course,” they say with a grin. “The bridge that spans the buildings serves as a pleasurable route for walks, and opens onto playgrounds that are suited to a range of ages. The spaces in between the apartments constitute alternative ground, which is important because the topography in this area of the Technion is really extreme.”

Chechik mentions favorably the way that the village blends into the natural forest.

“There is a sense that the buildings are well integrated into the forest. Old trees stayed put and the buildings kind of squeeze between them. More than once we have come upon wild boars and jackals,” he adds.

However, it would seem that the very spirit of cooperation and intimacy among the tenants could sometimes be problematic. The balconies are rarely used because they can be observed by anyone who happens to walk across the bridge. The same problem also exists in the apartments adjacent to the bridge.

The Graduate Student Village is one of the most important projects unveiled in Israel this year, if not the most important. It is a tremendous gesture toward the human scale as well as the natural scale of the Carmel, and it provides a healthy platform for the formation of a vibrant community and for the exchange of knowledge and opinions.

The success of the village is especially striking in view of the social protests of the summer and the demand for quality and affordable housing. It presents a realistic model for mass housing but succeeds in preserving a high level of architecture and design.

Bridge to Somewhere ~ Stanley Shalom Zielony Graduate Student Village, Technion City.

Blogged from Ha’aretz
Published 02:56 17.11.11
Latest update 02:56 17.11.11

The real innovation in the Technion’s new graduate housing lies in the bridges connecting the dorms, helping create communities of thinkers.

By Noam Dvir

The bridges of the new Graduate Students Village on the Technion campus in Haifa are bringing together a community of young researchers and scientists.

The village’s seven residential buildings are connected to each other by a system of wood and steel bridges that stand about eight meters above ground. Every afternoon these fill up with hundreds of parents and children who come down from their apartments to meet, talk and play. At the connecting points between the bridges and the buildings there are generous public spaces, equipped with wooden benches and wireless Internet. Parents can easily keep an eye on their children as they play in one of the playgrounds nearby.

The graduate student apartments with the bridge, which acts as a meeting place, a walkway and a place for leisure.

The Graduate Students Village is part of the Technion’s broad plan for attracting young minds, master’s and doctoral students who may become the next Nobel Prize winners. The model is simple: affordable housing, around NIS 1,700 per apartment including utilities, which enables students to concentrate on their research while assimilating into a cohesive community, and encourages them to settle down in the future at the Technion and in Haifa.

About eight years ago the Technion announced an architecture competition for a contemporary and appealing student village. Out of some 70 submissions to the competition, five architects made it to the final round, and the panel of judges ultimately chose the design submitted jointly by the architects Gaby Schwartz and Gidi Bar Orian.

The pair had studied architecture together at the Technion in the 1980s, so the project was a sort of homecoming. Bar Orian is known for his involvement in the design and preservation of residential buildings in Tel Aviv. Schwartz (of Schwartz Besnosoff Architects ) made his name with outstanding public buildings such as the new library at Kinneret College on the Sea of Galilee.

The village is located on the southwestern side of the campus, far away from the academic department buildings, and overlooks a natural and built landscape. The first decision that the architects made was to keep the natural forest in place far as was possible.

“Initially we thought of building low attached units, what is called a carpet, but the neighbors on the hill opposite always had a green landscape here and we didn’t want to spoil it for them,” Schwartz says. “Another decision was to avoid building huge support walls of the kind familiar in Haifa and to let the buildings become absorbed inward into the landscape.”

The chosen solution was a group of seven buildings, each five-stories high, that stand perpendicular to the mountain, with playgrounds and lawns between them. In the future, a community center will go up south of the residential buildings, and is set to include a kindergarten, clubhouse, and lecture hall.

Each building has some 30 apartments (218 in the housing complex overall ), which are arranged around three stairwells. Apartment sizes range from 60 to 100 square meters, with some having the option of “shifting” a room from one apartment to another to make it bigger or smaller.

The most important and innovative design component is a system of bridges that link up the interim levels of all the buildings and allow tenants to move around freely without needing to cross roads.

The experience of walking among the treetops is thrilling, and is reminiscent of works by the Japanese artist Tetsu Kondu, who deals with examining the relationship between man and heaven and earth. The buildings themselves look like giant masses that have had chunks “bitten” off.

“It’s meant to bring the landscape into the apartments,” Schwartz explains.

The seven buildings were intended for intensive use and wear and tear, so durable materials were selected – plaster for the facades, exposed concrete, suspended metal blinds, brick wall cover in the stairwells, and wooden lattices that create a separation between public- and semi-public spaces.

The entire village echoes the architecture of public housing complexes from the 1950s and 60s, particularly the bridge buildings designed by the architects Munio Gitai-Weinraub and Al Mansfeld in the Ramat Hadar neighborhood of Haifa. There too, the buildings are divided at mid-point by a public level that contains various usages for the benefit of the tenants, such as storage rooms and even a grocery store.

Forest living

Schwartz and Bar Orian agree with the comparison, but say their version takes the idea a step forward. “The public housing complexes in Israel were designed without any connection to the site. They were positioned at random without any link to the ground conditions. We tried to converse with the environment and with nature. The buildings in the village are ‘deformed’ in order to adjust to the landscape.”

The architects Liran Chechik and Nitzan Kalush have been living in the village for the past nine months. They moved there from junior faculty housing after their family grew. They deem the village a successful project, with “a whiff of colleges in Europe,” that enables community life and cooperation and makes you feel like sticking around for a long time.

“The public spaces have had a lot put into them, and generate a pretty lively community life – all relative to the Technion of course,” they say with a grin. “The bridge that spans the buildings serves as a pleasurable route for walks, and opens onto playgrounds that are suited to a range of ages. The spaces in between the apartments constitute alternative ground, which is important because the topography in this area of the Technion is really extreme.”

Chechik mentions favorably the way that the village blends into the natural forest.

“There is a sense that the buildings are well integrated into the forest. Old trees stayed put and the buildings kind of squeeze between them. More than once we have come upon wild boars and jackals,” he adds.

However, it would seem that the very spirit of cooperation and intimacy among the tenants could sometimes be problematic. The balconies are rarely used because they can be observed by anyone who happens to walk across the bridge. The same problem also exists in the apartments adjacent to the bridge.

The Graduate Student Village is one of the most important projects unveiled in Israel this year, if not the most important. It is a tremendous gesture toward the human scale as well as the natural scale of the Carmel, and it provides a healthy platform for the formation of a vibrant community and for the exchange of knowledge and opinions.

The success of the village is especially striking in view of the social protests of the summer and the demand for quality and affordable housing. It presents a realistic model for mass housing but succeeds in preserving a high level of architecture and design.

Technion Harvey Prize 2011

Harvey Prize 2011 Winners Announced
Date: 13/11/2011
Prof. Sir Richard Friend of the University of Cambridge, UK, and Prof. Judea Pearl from the
University of California, Los Angeles, are the winners of the Technion’s 2011 Harvey Prize in Science and Technology. The prize ceremony will take place at Technion, on March 29.

Sir Richard Friend, Cavendish Professor of Physics at the University of Cambridge, pioneered the physics, materials science and engineering of semiconductor devices made with carbon-based polymers and demonstrated their successful operation in field-effect transistors, in both light-emitting and photovoltaic diodes as well as in lasers. In pursuing the burgeoning development of this exciting technology, he founded two successful spin-off companies – Cambridge Display Technology Ltd. and Plastic Logic Ltd. The Harvey Prize is awarded to Prof. Sir Richard Friend in recognition of his outstanding contributions to science and technology, which are already making an impact on the semi-conductor industry and our lives.

Sir Richard also holds the appointment of Distinguished Visiting Professor at Technion. He
was knighted by the Queen in 2003 for services to physics.

Judea Pearl, Professor of Computer Science at the University of California, Los Angeles, through his wide-ranging and keen research, laid the theoretical foundations for knowledge representation and reasoning in computer science. His theories for inference under uncertainty, and most notably the Bayesian network approach, have profoundly influenced diverse fields such as artificial intelligence, statistics, philosophy, health, economics, social sciences, and cognitive sciences. The Harvey Prize is awarded to Prof. Pearl in recognition of his foundational work that has touched a multitude of spheres of modern life.

Judea Pearl completed his bachelor’s degree at Technion in 1960.

First awarded in 1972, Technion’s prestigious Harvey Prize was created as a bridge of goodwill between Israel and the nations of the world. It is considered a good predictor of the Nobel Prize.

Technion Harvey Prize 2011

Harvey Prize 2011 Winners Announced
Date: 13/11/2011
Prof. Sir Richard Friend of the University of Cambridge, UK, and Prof. Judea Pearl from the
University of California, Los Angeles, are the winners of the Technion’s 2011 Harvey Prize in Science and Technology. The prize ceremony will take place at Technion, on March 29.

Sir Richard Friend, Cavendish Professor of Physics at the University of Cambridge, pioneered the physics, materials science and engineering of semiconductor devices made with carbon-based polymers and demonstrated their successful operation in field-effect transistors, in both light-emitting and photovoltaic diodes as well as in lasers. In pursuing the burgeoning development of this exciting technology, he founded two successful spin-off companies – Cambridge Display Technology Ltd. and Plastic Logic Ltd. The Harvey Prize is awarded to Prof. Sir Richard Friend in recognition of his outstanding contributions to science and technology, which are already making an impact on the semi-conductor industry and our lives.

Sir Richard also holds the appointment of Distinguished Visiting Professor at Technion. He
was knighted by the Queen in 2003 for services to physics.

Judea Pearl, Professor of Computer Science at the University of California, Los Angeles, through his wide-ranging and keen research, laid the theoretical foundations for knowledge representation and reasoning in computer science. His theories for inference under uncertainty, and most notably the Bayesian network approach, have profoundly influenced diverse fields such as artificial intelligence, statistics, philosophy, health, economics, social sciences, and cognitive sciences. The Harvey Prize is awarded to Prof. Pearl in recognition of his foundational work that has touched a multitude of spheres of modern life.

Judea Pearl completed his bachelor’s degree at Technion in 1960.

First awarded in 1972, Technion’s prestigious Harvey Prize was created as a bridge of goodwill between Israel and the nations of the world. It is considered a good predictor of the Nobel Prize.